JUSTIN LAUDICK: Open Payments
NPI 1609393818 · OTTOVILLE, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$738 in 42 payments from 11 companies in 2025. Trend: 2023 $597 · 2024 $687 · 2025 $738
Food & beverage: $738
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $222 |
| AstraZeneca Pharmaceuticals LP | 8 | $152 |
| Novo Nordisk Inc | 4 | $83 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $80 |
| Sumitomo Pharma America, Inc. | 3 | $62 |
| Lilly USA, LLC | 2 | $35 |
| Amgen Inc. | 2 | $33 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| SHIELD THERAPEUTICS INC | 1 | $20 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $16 |
Products named: VRAYLAR, CAPLYTA, GEMTESA, AIRSUPRA, FARXIGA, QULIPTA, Ozempic, MOUNJARO.
Industry payments across OH — which companies pay providers there.
